Latest Information Update: 08 Nov 2006
At a glance
- Originator Roche
- Mechanism of Action Thrombopoietin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombocytopenia
Most Recent Events
- 08 Nov 2006 Discontinued - Preclinical for Thrombocytopenia in Germany (unspecified route)
- 13 Mar 2001 No-Development-Reported for Thrombocytopenia in Germany (Unknown route)
- 12 Jan 1999 New profile